ReviewMediators of inflammation2014
Chagas disease cardiomyopathy: immunopathology and genetics.
Review in Mediators of inflammation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 122 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
122 citing papers in PubMed, 7 syntheses or guidelines pooled it, 211 citations in OpenAlex.
- SBC Guideline on the Diagnosis and Treatment of Patients with Cardiomyopathy of Chagas Disease - 2023.Arquivos brasileiros de cardiologia · 2023Guideline
- Galectin-3 and fibrosis intensity in Chronic Chagas Cardiomyopathy: a systematic review.Revista do Instituto de Medicina Tropical de Sao Paulo · 2022Pooled it
- Genetic polymorphisms of IL17A associated with Chagas disease: results from a meta-analysis in Latin American populations.Scientific reports · 2020Pooled it
- Association of IL18 genetic polymorphisms with Chagas disease in Latin American populations.PLoS neglected tropical diseases · 2019Pooled it
- Single nucleotide polymorphisms of cytokine-related genes and association with clinical outcome in a Chagas disease case-control study from Brazil.Memorias do Instituto Oswaldo Cruz · 2018Pooled it
- Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy.The Cochrane database of systematic reviews · 2016 · on this mapPooled it
- Increased mortality attributed to Chagas disease: a systematic review and meta-analysis.Parasites & vectors · 2016Pooled it
- Omega-3 supplementation on inflammatory markers in patients with chronic Chagas cardiomyopathy: a randomized clinical study.Nutrition journal · 2017Trial
- Diagnostic performance of the TR Chagas Bio-Manguinhos rapid test for detecting anti-Trypanosoma cruzi IgG in human samples from three Southern Cone countries.PLoS neglected tropical diseases · 2026Article
- Evaluation of the autonomic nervous system in autochthonous patients from Amazon with acute Chagas disease treated with benznidazole.PLoS neglected tropical diseases · 2026Article
- Effects of MK-886, an inhibitor of the 5-lipoxygenase-activating protein, on peripheral blood mononuclear cells from patients with Chagas' heart disease.Revista da Sociedade Brasileira de Medicina Tropical · 2026Article
- Single-Cell Targeted Transcriptomics Reveals Subset-Specific Immune Signatures Differentiating Asymptomatic and Cardiac Patients With Chronic Chagas Disease.The Journal of infectious diseases · 2025Article
- The Role of Immunogenetics in the Host-Parasite Interaction of Chagas Disease: Implications for Personalized Medicine.Tropical medicine and infectious disease · 2025Review
- Article
- Estimating the health and economic burden of Chagas cardiomyopathy in the United States: a population-based analysis.Lancet regional health. Americas · 2025Article
- Trypanosoma cruzi DTU TcI disproportionately associated with fatal T. cruzi myocarditis in dogs in Texas, USA.Veterinary parasitology, regional studies and reports · 2025Article
- Intermittent suppressive posaconazole therapy is ineffective at mitigating cardiac and digestive tract pathologies in an experimental model of chronic Chagas disease.Antimicrobial agents and chemotherapy · 2025Article
- Cardiac and Digestive Forms of Chagas Disease: An Update on Pathogenesis, Genetics, and Therapeutic Targets.Mediators of inflammation · 2025Review
- Higher T-bet and IFN-γ expression in advanced chagasic megaesophagus indicates Th1 response in the chronic phase.Revista do Instituto de Medicina Tropical de Sao Paulo · 2025Article
- Role of glucocorticoid receptor expression in Chronic Chagas Cardiomyopathy: implications for inflammation and cardiac hypertrophy.Frontiers in endocrinology · 2025Article
62 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chagas disease, caused by the protozoan Trypanosoma cruzi, is endemic in Latin America and affects ca. 10 million people worldwide. About 30% of Chagas disease patients develop chronic Chagas disease cardiomyopathy (CCC), a particularly lethal inflammatory cardiomyopathy that occurs decades after the initial infection, while most patients remain asymptomatic. Mortality rate is higher than that of noninflammatory cardiomyopathy. CCC heart lesions present a Th1 T-cell-rich myocarditis, with cardiomyocyte hypertrophy and prominent fibrosis. Data suggest that the myocarditis plays a major pathogenetic role in disease progression. Major unmet goals include the thorough understanding of disease pathogenesis and therapeutic targets and identification of prognostic genetic factors. Chagas disease thus remains a neglected disease, with no vaccines or antiparasitic drugs proven efficient in chronically infected adults, when most patients are diagnosed. Both familial aggregation of CCC cases and the fact that only 30% of infected patients develop CCC suggest there might be a genetic component to disease susceptibility. Moreover, previous case-control studies have identified some genes associated to human susceptibility to CCC. In this paper, we will review the immunopathogenesis and genetics of Chagas disease, highlighting studies that shed light on the differential progression of Chagas disease patients to CCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.